Bariatric surgery is now recognized not just for its profound clinical benefits in obesity and type 2 diabetes (T2D) —including significant weight loss, improved life expectancy, reduced medication burden, and better quality of life—but also for its potential economic impact. Recent analyses, such as the large US cohort study by Sloan et al., demonstrate that after bariatric surgery, total healthcare expenditure for patients with T2D declines by 28% , driven primarily by a significant reduction in medication costs. These savings are apparent from the first year post-surgery and are sustained over 5.5 years , despite the initial investment cost of surgery.
While reductions in costs are most dramatic in systems where surgery is less expensive, even in higher-cost systems, long-term economic models suggest surgery may become cost-saving over 10–15 years. Direct cost savings complement…
